FDA grants Tectonic TX2100 Fast Track status for HHT
TECX•The FDA granted Fast Track designation to Tectonic’s TX2100 for hereditary hemorrhagic telangiectasia and cleared an IND for a Phase 1b U.S. trial. Tectonic targets starting the trial by year-end 2026.
1. Trial plans
The FDA granted Fast Track designation to TX2100 for treating hereditary hemorrhagic telangiectasia and cleared an IND to start a Phase 1b U.S. trial in patients with the condition. Tectonic targets initiating the trial by year-end 2026.
